Glutamate oxaloacetate transaminase: A new key in the dysregulation of glutamate in migraine patients

Cephalalgia

Volumn 33, Issue 14, 2013, Pages 1148-1154

  Campos, Francisco ^a   Sobrino, Tomás ^a   Pérez Mato, María ^a   Rodríguez Osorio, Xiana ^b   Leira, Rogelio ^b   Blanco, Miguel ^a   Mirelman, David ^c,d   Castillo, José ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^c WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^d Instituto de Salud Carlos III   (Spain)

Author keywords

Blood; glutamate; glutamate oxaloacetate transaminase; migraine

Indexed keywords

ASPARTATE AMINOTRANSFERASE; GLUTAMIC ACID;

ADULT; ARTICLE; BLOOD SAMPLING; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; ENZYME ACTIVITY; EPISODIC MIGRAINE; FEMALE; HUMAN; MALE; MIGRAINE WITH AURA; MIGRAINE WITHOUT AURA;

BLOOD; GLUTAMATE; GLUTAMATE OXALOACETATE TRANSAMINASE; MIGRAINE;

ADULT; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; GLUTAMIC ACID; HUMANS; MALE; MIGRAINE DISORDERS; YOUNG ADULT;

EID: 84885007123     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1177/0333102413487444     Document Type: Article

References (32)

1. Bloudek LM, Stokes M, Buse DC, et al. Cost of healthcare for patients with migraine in five European countries: Results from the International Burden of Migraine Study (IBMS). J Headache Pain. 2012 ; 13: 361-378
2. Ferrari A, Spaccapelo L, Pinetti D, et al. Effective prophylactic treatments of migraine lower plasma glutamate levels. Cephalalgia. 2009 ; 29: 423-429
3. Martínez F, Castillo J, Rodríguez JR, et al. Neuroexcitatory amino acid levels in plasma and cerebrospinal fluid during migraine attacks. Cephalalgia. 1993 ; 13: 89-93
4. Castillo J, Martínez F, Corredera E, et al. Amino acid transmitters in patients with headache during the acute phase of cerebrovascular ischemic disease. Stroke. 1995 ; 26: 2035-2039
5. Edvinsson L, Villalón CM, MaassenVanDenBrink A. Basic mechanisms of migraine and its acute treatment. Pharmacol Ther. 2012 ; 136: 319-333
6. Goadsby PJ, Classey JD. Glutamatergic transmission in the trigeminal nucleus assessed with local blood flow. Brain Res. 2000 ; 875: 119-124
7. Ramadan NM. The link between glutamate and migraine. CNS Spectr. 2003 ; 8: 446-449
8. Kertesz S, Kapus G, Gacsalyi I, et al. Deramciclane improves object recognition in rats: Potential role of NMDA receptors. Pharmacol Biochem Behav. 2010 ; 94: 570-574
9. Wang M, Chazot PL, Ali S, et al. Effects of NMDA receptor antagonists with different subtype selectivities on retinal spreading depression. Br J Pharmacol. 2012 ; 165: 235-244
10. Campos F, Sobrino T, Ramos-Cabrer P, et al. Neuroprotection by glutamate oxaloacetate transaminase in ischemic stroke: An experimental study. J Cereb Blood Flow Metab. 2011 ; 31: 1378-1386
11. Nagy D, Marosi M, Kis Z, et al. Oxaloacetate decreases the infarct size and attenuates the reduction in evoked responses after photothrombotic focal ischemia in the rat cortex. Cell Mol Neurobiol. 2009 ; 29: 827-835
12. Teichberg VI, Cohen-Kashi-Malina K, Cooper I, et al. Homeostasis of glutamate in brain fluids: An accelerated brain-to-blood efflux of excess glutamate is produced by blood glutamate scavenging and offers protection from neuropathologies. Neuroscience. 2009 ; 158: 301-308
13. Campos F, Sobrino T, Ramos-Cabrer P, et al. Oxaloacetate: A novel neuroprotective for acute ischemic stroke. Int J Biochem Cell Biol. 2012 ; 44: 262-265
14. Olesen J. International Classification of Headache Disorders, Second Edition (ICHD-2): Current status and future revisions. Cephalalgia. 2006 ; 26: 1409-1410
15. Lipton RB, Stewart WF, Diamond S, et al. Prevalence and burden of migraine in the United States: Data from the American Migraine Study II. Headache. 2001 ; 41: 646-657
16. Campos F, Sobrino T, Ramos-Cabrer P, et al. High blood glutamate oxaloacetate transaminase levels are associated with good functional outcome in acute ischemic stroke. J Cereb Blood Flow Metab. 2011 ; 31: 1387-1393
17. Campos F, Rodríguez-Yáñez M, Castellanos M, et al. Blood levels of glutamate oxaloacetate transaminase are more strongly associated with good outcome in acute ischaemic stroke than glutamate pyruvate transaminase levels. Clin Sci (Lond). 2011 ; 121: 11-17
18. Ferrari MD, Odink J, Bos KD, et al. Neuroexcitatory plasma amino acids are elevated in migraine. Neurology. 1990 ; 40: 1582-1586
19. D'Andrea G, Cananzi AR, Joseph R, et al. Platelet glycine, glutamate and aspartate in primary headache. Cephalalgia. 1991 ; 11: 197-200
20. Cananzi AR, D'Andrea G, Perini F, et al. Platelet and plasma levels of glutamate and glutamine in migraine with and without aura. Cephalalgia. 1995 ; 15: 132-135
21. Alam Z, Coombes N, Waring RH, et al. Plasma levels of neuroexcitatory amino acids in patients with migraine or tension headache. J Neurol Sci. 1998 ; 156: 102-106
22. Rajda C, Tajti J, Komoroczy R, et al. Amino acids in the saliva of patients with migraine. Headache. 1999 ; 39: 644-649
23. Peres MF, Zukerman E, Senne Soares CA, et al. Cerebrospinal fluid glutamate levels in chronic migraine. Cephalalgia. 2004 ; 24: 735-739
24. Vieira DS, Naffah-Mazzacoratti Mda G, Zukerman E, et al. Glutamate levels in cerebrospinal fluid and triptans overuse in chronic migraine. Headache. 2007 ; 47: 842-847
25. Vaccaro M, Riva C, Tremolizzo L, et al. Platelet glutamate uptake and release in migraine with and without aura. Cephalalgia. 2007 ; 27: 35-40
26. Ragginer C, Lechner A, Bernecker C, et al. Reduced urinary glutamate levels are associated with the frequency of migraine attacks in females. Eur J Neurol. 2012 ; 19: 1146-1150
27. Leira R, Rodríguez R. Diet and migraine [in Spanish]. Rev Neurol. 1996 ; 24: 534-538
28. O'Kane RL, Martínez-López I, DeJoseph MR, et al. Na(+)-dependent glutamate transporters (EAAT1, EAAT2, and EAAT3) of the blood-brain barrier. A mechanism for glutamate removal. J Biol Chem. 1999 ; 274: 31891-31895
29. Tomkins O, Kaufer D, Korn A, et al. Frequent blood-brain barrier disruption in the human cerebral cortex. Cell Mol Neurobiol. 2001 ; 21: 675-691
30. Gursoy-Ozdemir Y, Qiu J, Matsuoka N, et al. Cortical spreading depression activates and upregulates MMP-9. J Clin Invest. 2004 ; 113: 1447-1155
31. Leira R, Sobrino T, Rodríguez-Yáñez M, et al. Mmp-9 immunoreactivity in acute migraine. Headache. 2007 ; 47: 698-702
32. Imamura K, Takeshima T, Fusayasu E, et al. Increased plasma matrix metalloproteinase-9 levels in migraineurs. Headache. 2008 ; 48: 135-139